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Abstract
Background: Visceral leishmaniasis is a parasitic disease associated with high mortality. The most important foci of visceral
leishmaniasis in Ethiopia are in the Northwest and are predominantly associated with high rates of HIV co-infection. Co-
infection of visceral leishmaniasis patients with HIV results in higher mortality, treatment failure and relapse. We have
previously shown that arginase, an enzyme associated with immunosuppression, was increased in patients with visceral
leishmaniasis and in HIV seropositive patients; further our results showed that high arginase activity is a marker of disease
severity. Here, we tested the hypothesis that increased arginase activities associated with visceral leishmaniasis and HIV
infections synergize in patients co-infected with both pathogens.
Methodology/Principal Findings:We recruited a cohort of patients with visceral leishmaniasis and a cohort of patients with
visceral leishmaniasis and HIV infection from Gondar, Northwest Ethiopia, and recorded and compared their clinical data.
Further, we measured the levels of arginase activity in the blood of these patients and identified the phenotype of arginase-
expressing cells. Our results show that CD4+ T cell counts were significantly lower and the parasite load in the spleen was
significantly higher in co-infected patients. Moreover, our results demonstrate that arginase activity was significantly higher
in peripheral blood mononuclear cells and plasma of co-infected patients. Finally, we identified the cells-expressing arginase
in the PBMCs as low-density granulocytes.
Conclusion: Our results suggest that increased arginase might contribute to the poor disease outcome characteristic of
patients with visceral leishmaniasis and HIV co-infection.
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Introduction
Visceral leishmaniasis (VL), a neglected tropical disease caused
by the parasite Leishmania (L.) donovani, is one of the most significant
vector-borne diseases in Ethiopia, with an estimated 4500 to 5000
new cases every year [2]. VL is associated with high mortality and
morbidity and hinders economic development. VL is worsened by
malnutrition and co-infections with HIV. In the region with the
highest endemicity for VL in Northwest Ethiopia, the prevalence
of HIV seropositivity among patients with VL has been shown to
be as high as 38% [1]. Patients with visceral leishmaniasis and
HIV infection (VL/HIV patients) display an increased susceptibility
to drug toxicity, increased leishmaniasis relapses and increased
mortality [1,3,4]; and accelerated progression to AIDS [5].
Both Leishmania and HIV are able to infect and replicate in
monocytes and macrophages and both pathogens mutually promote
their replication in these host cells. Several studies have shown that
infection of myeloid cells with Leishmania parasites promotes HIV
replication [6,7,8]. Equally, HIV not only promotes Leishmania
uptake by macrophages [9], but also increases parasite replication in
monocytes [10]; this is in agreement with the observation of
increased parasitemia in VL/HIV patients [11].
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One of the immunological hallmarks of VL and HIV infections
is a diminished ability of PBMCs from these patients to respond to
recall antigens [12,13,14]. We have recently shown that the
activity of the enzyme arginase is increased in patients with visceral
leishmaniasis (VL patients) and in HIV seropositive patients (HIV
patients) with low CD4+ T cell counts [15,16]. Arginase hydrolyzes
L-arginine to urea and ornithine, which is further metabolized into
polyamines. Arginase can also be upregulated in myeloid cells and
has been shown to impair T cell responses by reducing the
bioavailability of L-arginine in the microenvironment. Since L-
arginine is essential for efficient T cell activation, this decrease
results in impaired T cell responses [17,18,19]. In both our HIV
[20] and VL [16] studies, increased arginase activity in PBMCs
was a marker of disease severity, and coincided with lower L-
arginine levels and impaired T cell responses.
Here, we tested the hypothesis that a synergistic increase in
arginase activity occurs in VL patients co-infected with HIV as
compared to VL patients, and therefore contributes to exacerbat-
ed disease outcomes.
Materials and Methods
Subjects and sample collection
The study was approved by the IRB of College of Medicine and
Health Science, University of Gondar, reference number 09/07/
2003. For this cross-sectional study, a cohort of 26 patients with
visceral leishmaniasis, but HIV seronegative uninfected (VL
patients) and 14 VL/HIV co-infected patients was recruited from
the Leishmaniasis Treatment and Research Center of Gondar
University Hospital; informed written consent was obtained from
each patient. All patients recruited in our study were migrant
workers and male.
The diagnosis of VL was based on positive serology (rK39,
DiaMed IT Leish, DiaMed AG, Cressiers/Morat, Switzerland)
and presence of amastigotes in spleen or bone marrow aspirates.
HIV seropositivity was based on the following tests: KHB
Shanghai Kehua Bio-engineering Co. Ltd and Chembio HIV 1/
2 STAT-PAK; Uni-Gold (Trinity Biotech PLC) was used to
resolve ambiguous results. Out of the 14 co-infected patients, 10
were primary VL patients and 4 had a relapse of VL. Relapse is
defined as follows: individuals diagnosed with visceral leishman-
iasis (clinical features and positive parasitology), after having been
successfully treated for primary VL and been discharged with an
improved medical condition or with a negative test of cure. Six
patients were already on anti-retroviral therapy (ART), the 8
remaining patients were initiated on ART after the treatment
against VL. The treatment was given according to the recom-
mendation of the National Guideline for Diagnosis, Treatment &
Prevention of Leishmaniasis in Ethiopia: VL patients HIV+
already on ART were treated with AmBisome (Gilaed Sciences
Ltd. (Ireland)) at a dose of 3–5 mg/kg daily or intermittently for 10
doses, up to a total dose of 40 mg/kg. VL patients HIV+ not on
ART were treated with SSG (20 mg/kg for 30 days) first and
started ART upon completion of the treatment against VL.
All the VL patients were treated with SSG for 30 days at a dose
of 20 mg/kg.
Informed written consent was obtained from each patient. The
median age of the VL patients was 22.061.0 years (range: 16–32
years) and that of VL/HIV co-infected patients was 33.061.9
years (range: 28–38 years).
Saliva was collected by spitting in a sterile 50 ml tube, after the
patients rinsed their mouth with clean water. The saliva sample
was immediately frozen at 220uC.
Ten to twenty ml of venous blood was collected into EDTA
tubes before the antileishmanial treatment started. Plasma was
isolated by centrifuging 1 ml of blood at 1800 rpm for 10 minutes
and was frozen at 220uC until further use. Peripheral blood
mononuclear cells (PBMCs) were isolated by density gradient
centrifugation on Histopaque-1077 (Sigma). Cells were washed in
phosphate buffered saline (PBS) and used straight away for flow
cytometry; PBMCs used for arginase and protein determination
were immediately resuspended in lysis buffer (0.1% Triton X-100,
25 mM Tris-HCl and 10 mM MnCl2, Sigma) and frozen at
220uC until further use.
Laboratory evaluation
CD4+ and CD8+ T cell counts were determined using a BD
Multi TEST kit (BD Biosciences) and acquisition was performed
using a FACSCalibur (BD Biosciences).
Liver and renal function tests were performed as part of the
routine management practice. The following reagents (HUMAN
Diagnostics) were used according to the manufacturer’s protocol:
GOT (ASAT); Aspartate aminotransferase liquiUV test; GPT
(ALAT), Alanine aminotransferase liquiUV test; ALP, Alkaline
Phosphatase liquicolor test; BUN (Blood Urea Nitrogen), Urea
liquicolor test; Creatinine, creatinine liquicolor test.
Determination of parasite burden: grading was assessed as
previously described in the splenic aspirates [21] and the same
grading system was applied for the bone marrow aspirates.
Determination of arginase activity
The enzymatic activity of arginase was measured as previously
described [15]. To activate arginase, 50 ml of PBMCs (resus-
pended in lysis buffer = 0.1% Triton X-100/10 mM MnCl2/
Author Summary
Visceral leishmaniasis (VL) in Ethiopia is caused by the
parasite Leishmania donovani. This disease has one of the
highest mortality rates: if left untreated, it is almost always
fatal. VL belongs to the most neglected tropical diseases,
affecting the poorest populations, for whom access to
diagnosis and effective treatment are often not available.
VL is worsened when the patients are co-infected with HIV.
We have recently shown that patients with visceral
leishmaniasis (VL patients) and HIV seropositive patients
(HIV+ patients) have increased levels of an enzyme,
arginase, in their blood. This enzyme has been shown to
prevent cells of the immune system from mounting an
efficient response and controlling the replication of the
virus in HIV+ patients or the parasites in VL patients. In this
study, we show that arginase is considerably higher in the
blood of VL/HIV co-infected patients as compared to VL
patients. Our results suggest that this abnormally high
arginase might contribute to the poor prognosis associat-
ed to VL/HIV patients.
Table 1. Clinical data.
VL patients VL/HIV patients p values
Spleen size (cm) 7.560.8 6.061.1 0.3086
Liver size (cm) 4.060.2 4.060.7 0.7379
Spleen and liver size =measurement below left costal margin and right
subcostal margin (respectively).
doi:10.1371/journal.pntd.0001977.t001
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25 mM Tris-HCl) were incubated for 10 min at 56uC. Arginine
hydrolysis was achieved by incubating the lysate with 50 ml of
0.5 M L-arginine (pH 9.7) at 37uC for 15–120 min. The reaction
was stopped with 400 ml of H2SO4 (96%)/H3PO4 (85%)/H2O (1/
3/7, v/v/v). Urea concentration was measured at 550 nm after
addition of 20 ml a-isonitrosopropiophenone (dissolved in 100%
ethanol), followed by heating at 100uC for 45 min.
To determine arginase activity in the plasma, urea concentra-
tions were first determined in the sera, without the activation and
hydrolysis steps; these values were subtracted from those obtained
by measuring the urea levels as described above.
One unit of enzyme activity is defined as the amount of enzyme
that catalyzes the formation of 1 mmol of urea per min.
Protein determination
To determine the protein concentration of lysed PBMC
samples, serial dilutions of each PBMC lysate were made in PBS
(Sigma). BCA Protein Assay Reagent (Pierce) was added to each
PBMC dilution following supplier’s recommendations. A bovine
serum albumin (BSA) standard (Pierce) was serially diluted using
PBS. Following 30 minutes incubation at 37uC, the optical density
(OD) was measured at 570 nm.
Flow cytometry
Antibodies used were as follows: anti-CD14 (BD Pharmingen:
cloneM5E2), and anti-CD15 (Clone H198, BD Pharmingen).
Anti-arginase I (HyCult Biotechnology: clone 6G3) and the isotype
control (BD Pharmingen: clone MOPC21) were coupled with
Alexa FluorR 488 (Molecular Probes). Cells were washed with
PBS, the fixation step was performed with 2% formaldehyde in
PBS and the permeabilization step with 0.5% saponin in PBS.
The determination of intracellular arginase was performed as
described in [15]. The percentages for the isotype controls were
,1.23%. Acquisition was performed using a FACSCalibur (BD
Biosciences) and data were analyzed using Summit v4.3 software.
Statistical analysis
Data were evaluated for statistical differences using a two-tailed
Mann-Whitney test (GraphPad Prism 5) and differences were
considered statistically significant at p,0.05. Unless otherwise
specified, results are expressed as median6SEM.
Results
Clinical data
For this study, a cohort of 26 VL patients and 14 VL/HIV co-
infected patients was recruited. All patients were male. The
duration of illness was defined as the number of weeks since the
patients noticed symptoms associated with visceral leishmaniasis:
the most common symptom that they refer to was fever, but could
also be weight loss, epistaxis, fatigue and abdominal swelling (as a
sign of enlarged spleen or liver). For those patients with relapsing
VL, the duration of illness only applies to the onset of the relapse.
Duration of illness ranged from 2–24 weeks among the VL
patients (461.2 weeks) and from 4–96 weeks among the VL/HIV
patients (2466.4 weeks)(data not illustrated). All patients had an
enlarged spleen and liver, but the differences between the two
groups were not significant (Table 1, p.0.05). Their liver and
kidney functions were assessed, and as shown in Table 2, all the
values were similar between VL and VL/HIV patients (p.0.05).
The parasite grade was significantly higher in splenic aspirates
from co-infected patients as compared to VL patients (6.060.3 vs
4.060.3, p,0.0001, Figure 1A). Parasite grade in the bone
marrow aspirates appeared similar in both groups, however,
it is difficult to draw a definite conclusion from these data, as
there were only 3 values for the VL/HIV co-infected patients
(Figure 1B).
The nutritional status of the two cohorts was assessed by
calculating their body mass index (BMI) and measuring their
upper arm circumference. As shown in Figure 2A, the medians
BMI of both VL and VL/HIV groups were remarkably low and
the median BMI of VL/HIV patients was similar to the BMI of
VL patients (VL: 16.560.3 and VL/HIV: 15.860.6, p=0.06).
Twenty-three out of 25 VL patients and 13 out of 14 VL/HIV
patients had a BMI,18.5; 12 out of 25 VL patients (48.0%) and
11 out of 14 VL/HIV patients (78.6%) had a BMI ,16.5;
indicative that the VL/HIV cohort was more severely malnour-
ished. Although the median upper arm circumference was lower in
the VL/HIV cohort than the VL cohort, this difference was not
Table 2. Liver and kidney functions assays.
VL VL/HIV P values
GOT (U/l) 49.069.3 28.0614.9 0.2033
GPT (U/l) 30.064.2 17.564.7 0.3505
ALP (U/l) 274.0641.1 401.06350.1 0.1900
Creatinine (mg/
dl)
1.160.2 0.960.1 0.1495
BUN (mg/dl) 14.464.1 13.763.2 0.8582
GOT= glutamic-oxaloacetic transaminase, GPT =Glutamic-pyruvic
transaminase, ALP =Alkaline phosphatase, BUN=blood urea nitrogen.
doi:10.1371/journal.pntd.0001977.t002
Figure 1. Parasite grade in spleen and bone marrow aspirates. The parasite grade was graded from 1+ to 6+ in smears from (A) spleen (VL
patients: n = 16, VL/HIV patients: n = 11) and (B) bone marrow (VL patients: n = 10, VL/HIV patients: n = 3). The straight line represents the median.
doi:10.1371/journal.pntd.0001977.g001
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statistically significant (Figure 2B, 21.060.5 cm vs 19.060.7 cm,
p=0.1210).
Both CD4+ and CD8+ T cell counts were below the normal
range in both groups of patients (Figures 3). Moreover, CD4+ T
cell counts were significantly lower in VL/HIV patients (VL:
173624.1, VL/HIV: 34.5613.5, p,0.0001, Figure 3A). Although
CD8+ T cell counts were below the normal range in both VL and
co-infected patients (164622.3 and 195641.9 respectively,
Figure 3B), the difference between the two groups was not
statistically significant (p=0.5799).
Increased arginase activity in VL/HIV co-infection
Our previous study had shown that arginase activity was higher
than normal in the blood of HIV+ patients [15] and in the blood
of VL patients [16]. In the present study, we tested the hypothesis
that arginase activity was even further increased in co-infected
patients. In order to reduce the number of venipunctures, we
tested whether arginase is detectable in saliva; our results show
that it is clearly measurable in saliva (Figure 4A), however, the
values obtained in each group were similar: VL: 70628.2 mU/ml
of saliva and VL/HIV: 80625.1 mU/ml (p=0.2925). Next we
measured the levels of arginase activity in PBMCs and in plasma.
The results in Figure 4B show that arginase activity was
statistically significantly higher in PBMCs from co-infected
patients (2036148.1 mU/mg protein) than those from VL
patients (94.2616.3, p=0.0308). Similar results were obtained
with the plasma: VL: 6.961.3 mU/ml vs VL/HIV:
13.161.6 mU/ml (p= 0.0162). These results show that arginase
activity is even higher in PBMCs and plasma of co-infected
patients as compared to VL patients. Finally, we determined the
phenotype of arginase-expressing cells among the PBMCs. Our
results are in agreement with our previous results [15,16,22] and
show that neutrophils are the main type of cells in the PBMCs that
express arginase. Indeed, in all 8 VL patients tested .98.9% of
CD15+ and ,0.24% were CD152 arginase+ (Figure 5A).
Similarly, in all 5 VL/HIV patients tested, .98.2% of CD15+
cells expressed arginase and ,0.31% are CD152 arginase+
(Figure 5B). These results demonstrate that neutrophils are the
main cells expressing arginase in the PBMCs of VL and VL/HIV
patients.
Discussion
The results of our study show that arginase levels are
significantly higher in VL/HIV coinfected patients than in VL
patients. We propose that increased arginase-mediated L-arginine
metabolism contributes to T cell dysfunction and as a conse-
quence, to the poor outcome associated with VL/HIV co-
infection. We and others have shown that higher arginase activity
coincides with lower levels of L-arginine and lower expression
levels of CD3f in T cells [15,16,23], suggesting that T cell
functions are compromised when activation occurs in the presence
of suboptimal levels of L-arginine. One of the main immunological
characteristics of both HIV and VL patients is the failure of their
PBMCs to respond efficiently to antigen-specific restimulation
[12,13,14,24,25]. This is even further impaired in VL/HIV co-
infected patients: PBMCs from these patients proliferate less and
produce considerably lower levels of IL-2 and IFN-c in response to
Leishmania and HIV antigenic restimulation [26]. And indeed, the
CD4+ T cell counts, which are closely associated with disease
severity and immune suppression [12,27,28,29] were significantly
lower in VL/HIV patients as compared to VL patients. The
results presented in our study could explain this weakened immune
response as we show that arginase, an enzyme with potent
immunosuppressive properties, is even further increased in the
PBMCs from VL/HIV patients. These higher levels of arginase
activity may also explain why VL/HIV patients develop more
Figure 2. BMI and upper arm circumference. (A) Measurements of BMI (VL patients: n = 25, VL/HIV patients: n = 14) and (B) circumference of the
upper arm (VL patients: n = 17, VL/HIV patients: n = 13). The straight line represents the median. NS = not significant.
doi:10.1371/journal.pntd.0001977.g002
Figure 3. CD4+ and CD8+ T cell counts. (A) CD4+ (VL patients: n = 17, VL/HIV patients: n = 14) and (B) CD8+ (VL patients: n = 17, VL/HIV patients:
n = 12) cell counts in the blood of controls were measured by flow cytometry. The straight line represents the median. Ethiopian national reference
range for CD4+ T cells counts (cells/ml of blood) = 500–1300; Ethiopian national reference range for CD8+ T cells counts (cells/ml of blood) = 320–1800.
NS = not significant.
doi:10.1371/journal.pntd.0001977.g003
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frequent opportunistic infections, such as tuberculosis and
pneumonia [5,30].
In addition to impairing T cell functions, arginase activity has
also been shown to favour parasite growth in macrophages:
arginase catabolises L-arginine into polyamines, which are the
main intracellular source of the polyamines necessary for the
growth of the parasites [31]. Similarly, polyamines also appear be
important for HIV replication, since blocking of a key enzyme in
polyamine synthesis efficiently suppresses HIV-1 replication [32].
Therefore it is possible that polyamines resulting from the
catabolism of L-arginine by arginase benefit both Leishmania and
HIV replication. This might also account for the higher parasite
grade in VL/HIV co-infected patients.
Arginase-expressing macrophages have been shown to promote
parasite growth in vitro in experimental models of leishmaniasis
[31,33], and increased arginase activity at the site of pathology is a
hallmark of nonhealing infections [31,34]. However, the pheno-
type of arginase-expressing cells in the lesions has not yet been
established. In human blood, the main arginase-expressing cell
types are neutrophils [35], myeloid suppressor cells [36] and
alternatively activated macrophages [37]. Here, we show that over
98% of CD15+ cells express arginase and only a minority of
CD14+ monocytes express arginase. We and others have
previously shown that a population of neutrophils co-purify with
PBMCs following density gradient centrifugation [15,37,38,39].
Because of their difference in density, these cells are referred to as
low-density granulocytes (LDGs). Our data from HIV patients
[20] and VL patients [16] suggest that these neutrophils have
degranulated and that an increased frequency of LDGs coincides
with disease severity: in HIV+ patients, we found a strong inverse
correlation between the percentages of LDGs and CD4+ T cells
counts [20], similar to that we found between arginase activity and
Figure 4. Arginase activity in saliva, PBMCs and plasma. The activity of arginase was measured by enzymatic assay in (A) Saliva (VL patients:
n = 16, VL/HIV patients: n = 13), (B) PBMCs (VL patients: n = 14, VL/HIV patients: n = 13) and (C) plasma (VL patients: n = 14, VL/HIV patients: n = 13). The
straight line represents the median. NS = not significant.
doi:10.1371/journal.pntd.0001977.g004
Figure 5. Phenotype of arginase expressing LDGs. PBMCs were isolated by density gradient from the blood of (A) one VL patient and (B) one
VL/HIV patient and the phenotype of arginase-expressing cell was measured by flow cytometry. Data show the results of one representative
experiment out of 8 independent experiments for the VL patients and 5 independent experiments for the VL/HIV patients.
doi:10.1371/journal.pntd.0001977.g005
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CD4+ T cell counts [15]; in our VL study, we showed that the
frequency of LDGs was significantly increased in PBMCs of
patients before treatment.
Further characterization of these cells in VL/HIV patients will
be essential to define how they contribute to exacerbated disease
outcomes.
Severe malnutrition was remarkably common in VL/HIV
patients: 78.6% of these patients had a BMI below 16.5.
Malnutrition is associated with lower levels of L-arginine in the
plasma [40,41,42] and we cannot exclude the possibility that
malnutrition in these patients also contributed to the diminished
levels of L-arginine in the plasma.
The spleen and liver sizes and the liver and kidney functions
were similar in the VL and the VL/HIV patients, this is in
agreement with the study by Hurisssa et al [1], that shows that the
clinical presentation were similar in both groups of patients. In
agreement too with the publication by Hurissa et al [1] was the
intriguing finding that the duration of illness was longer in VL/
HIV patients. The duration of illness was defined by the patient,
from the onset of his symptoms, and it is therefore difficult to
determine whether this information was accurate. However, it is
possible that since T cells from co-infected patients display
significantly more impaired immune functions [26], VL/HIV
patients might therefore experienced symptoms earlier than the
VL patients. It was also noticed that in contrast to VL patients, co-
infected patients may not mount fever or only low grade fever, this
would delay the process of seeking medical attention.
The development of new treatments that address the specific
requirements associated with co-infection is of utmost importance.
Our results have important implications for understanding the
pathogenesis of VL/HIV co-infections. This may open up new
therapeutic avenues to target dysregulated T cells responses.
Further, the results of our study are not only applicable to
understanding VL/HIV co-infections, but might also be relevant
in understanding the exacerbated disease outcome associated with
other co-infections.
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